Mankind Pharma , a prominent player in the Indian pharmaceutical industry, has released its financial results for the second quarter of fiscal year 2026, revealing a mixed performance amidst ongoing organizational changes and market challenges.

Q2 FY26 Financial Highlights

H1 FY26 Performance

Segment-wise Performance

Domestic Business

• Revenue: ₹3,184.00 crores (15.00% YoY growth)
• Organic growth: ~6%
• Secondary sales growth: 6.30% (vs. IPM growth of 7.20%)

Export Business

• Revenue: ₹513.00 crores (83.00% YoY growth)
• Organic growth: Mid-single digits

OTC Business

• Revenue: ₹226.00 crores (3.00% YoY decline)

Key Developments and Challenges

1. BSV Consolidation: The significant growth in both domestic and export revenues was primarily driven by the consolidation of BSV.

2. Supply Chain Disruption: The company faced challenges due to the rollout of new GST rates, impacting its supply chain.

3. Chronic Therapy Focus: The share of chronic therapy increased to 37.10% from 35.10% in the previous year, indicating a strategic shift in the company's portfolio.

4. R&D Investment: R&D expenses increased to 2.90% of sales, up from 1.90% in the previous year, highlighting the company's focus on innovation.

5. Organizational Transformation: Management acknowledged underperformance against expectations, citing significant workforce changes across the organization as part of ongoing transformation efforts.

Outlook

Despite the challenges, Mankind Pharma's management remains optimistic about the future:

• Expects growth recovery in the second half of FY26
• Maintains BSV growth guidance of 18-20% for FY26

The company's performance in Q2 FY26 reflects both the opportunities and challenges in the pharmaceutical sector. While revenue growth remains strong, particularly bolstered by the BSV consolidation, Mankind Pharma is navigating through a period of internal transformation and external market pressures. The increased focus on chronic therapies and higher R&D investment suggests a strategic pivot towards long-term growth and innovation.

As the company works through its organizational changes and adapts to new market dynamics, investors and industry observers will be keenly watching how these efforts translate into performance in the coming quarters.

Mankind Pharma , a prominent player in the Indian pharmaceutical sector, has announced its financial results for the quarter and half year ended September 30, 2025, showcasing significant revenue growth.

Key Financial Highlights

Revenue Growth and Profit Increase

Mankind Pharma demonstrated strong financial performance in the second quarter of FY2026. The company reported revenue from operations of ₹2,608.78 crores, representing a 15.4% increase from ₹2,261.43 crores in the same quarter of the previous year. This substantial rise in revenue indicates robust demand for the company's pharmaceutical products.

The company's bottom line also showed significant improvement. The net profit for Q2 FY2026 stood at ₹458.90 crores, marking a 26.5% increase from the ₹362.68 crores reported in the same quarter of the previous year.

Half-Year Performance

For the six-month period ended September 30, 2025, Mankind Pharma's revenue reached ₹4,956.80 crores, compared to ₹4,497.80 crores in the corresponding period of the previous year, indicating continued growth momentum.

Earnings Per Share

The company's earnings per share (EPS) for the quarter improved to ₹11.10, up from ₹10.00 in the prior year quarter, reflecting an 11% increase.

Corporate Governance

The Board of Directors approved these unaudited standalone and consolidated financial results at their meeting held on November 6, 2025, demonstrating the company's commitment to timely financial reporting and transparency.

Ongoing Legal Proceedings

Mankind Pharma continues to face ongoing income tax proceedings initiated by the Income Tax Department under Section 132 of the Income Tax Act, 1961. The company has noted that appeals are currently pending with appellate tax authorities.

The strong financial performance, particularly in revenue growth and profitability, positions Mankind Pharma favorably in the pharmaceutical market. However, the ongoing tax proceedings may require careful management attention in the coming periods.